Page 19 - Aurobindo Pharma

Aurobindo strengthens its presence in Europe

The Portuguese acquisition should rub off positively on the stock

Aurobindo buys Portuguese firm for Rs 963 crore

To become leader in Portugal's generic drugs market

Aurobindo Pharma to buy Portugal-based Generis for Rs 969 cr

Acquisition includes Generis' facility in Amadora which can manufacture 1.2 bn tablets annually

Compass: Concerns overdone on Aurobindo Pharma

FDA observations, lawsuit impact to be negligible while earnings momentum is expected to continue

Aurobindo Pharma Unit 1 gets US FDA observations

The plant is used for manufacturing of active pharmaceutical ingredients

Aurobindo pharma to acquire select products in France from Teva

Both companies intend to ensure continuity of the supply of the products to the market

Improving margin to up Aurobindo earnings

Even as revenue growth may soften due to high base, rising operating profit margin bodes well for firm

Aurobindo Pharma Q2 net profit up 33% at Rs 605 crore

Company's income from operations grew 12.19% to Rs 3775.45 crore

US FDA gives tentative approval for Aurobindo's generic HIV drug

ViiV Healthcare, Aurobindo Pharma signed an agreement allowing Aurobindo to supply Dolutegravir 50 mg in 92 licensed countries

Aurobindo Pharma gains on tentative nod for HIV drug

The stock up 4% to Rs 842 after the company has received the tentative approval of Dolutegravir 50mg from USFDA for the treatment of HIV.

Aurobindo Pharma plans to launch 19 drugs in US in next 3 quarters

The company has already 20 products in the US market under OTC segment

Aurobindo, Intas seek to boost Europe business with Teva bid

Indian drug makers Aurobindo Pharmaceuticals and Intas are in the race to acquire Teva's generic drugs in Britain as a part of their plans to expand their European businesses

Aurobindo beats the pharma blues

Stock gains 7% as US formulation business growth boosts profit, net debt reduces by $115 million

Aurobindo Pharma gains on strong Q1 results

The stock rallied 6% to Rs 778 after the company reported 24% YoY jump in consolidated net profit at Rs 585 crore in Q1FY17.

Aurobindo Pharma Q1 net profit up 24% at Rs 584 crore

The net profit for the year ago period was Rs 471.3 crore

Aurobindo Pharma to set up vaccine manufacturing facility

It, however, did not disclose information related to location of the manufacturing facility

Aurobindo Pharma gets USFDA nod for anti-infective injection

Company is expected to launch Linezolid injection in the second quarter of the 2016-17

Aurobindo gets ready to play with the big boys

Aurobindo is in a race with two other multinationals for the acquisition of Teva Pharmaceutical's European assets

Aurobindo's anti-cholesterol drug gets USFDA nod

Rosuvastatin Calcium has a market size of $6.7 billion

Aurobindo Pharma gains on USFDA approval for Rosuvastatin calcium tablets

The stock moved higher by 4% to Rs 788 on the BSE.